KAT2A and acute myeloid leukemia: Authors such as Tzelepis et al., incorporated genome-wide CRISPR screening in distinguishing more than 100 essential AML-gene triggers, among which KAT2A was chosen as a promising therapeutic target against AML (Tzelepis et al., 2016).